Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018401 · ClinicalTrials.gov registry record
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
A clinical trial of Hereditary Hemorrhagic Telangiectasia (HHT), sponsored by Massachusetts General Hospital.
- Active
- Registry status
- 62
- Enrollment target
- 11
- Study locations
NCT07018401 is a study of Hereditary Hemorrhagic Telangiectasia (HHT) that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 62 participants, roughly in line with the 66-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target. The trial reports 11 study locations across 10 states.
The verdict
NCT07018401, a study of Hereditary Hemorrhagic Telangiectasia (HHT), is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 62 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinical trial participants following completion of the double-blind, placebo-controlled study.
Conditions Studied
Interventions
- DRUG Pomalidomide
Study Locations (11)
California
- University of California-San Diego - San Diego
- University of California-San Francisco - San Francisco
Florida
- University of Florida - Gainesville
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- University of North Carolina, Chapel HIll - Chapel Hill
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2026-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07018401
The ClinicalTrials.gov registry entry for NCT07018401 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 66-participant average among 3 other Hereditary Hemorrhagic Telangiectasia (HHT) trials with a reported enrollment target. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hereditary Hemorrhagic Telangiectasia (HHT) appearing as the primary indexed condition, and to 1 intervention - of which Pomalidomide is the first listed.
NCT07018401 reports 11 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT07018401 about?
NCT07018401 is a clinical study titled "Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study". This is a multicenter U.S. longitudinal study evaluating patients with hereditary hemorrhagic telangiectasia who participated in the PATH-HHT clinical trial of pomalidomide for the treatment of HHT. This study is a longitudinal assessment of safety and effectiveness of pomalidomide in HHT in clinica...
What is the current status of trial NCT07018401?
This trial is currently active not recruiting. The enrollment target is 62 participants. The study started on 2024-05-01. Estimated completion is 2026-06-01.
What conditions does trial NCT07018401 study?
This clinical trial studies the following conditions: Hereditary Hemorrhagic Telangiectasia (HHT).
What interventions are being tested in trial NCT07018401?
The interventions under investigation include: Pomalidomide (DRUG).
Who is sponsoring clinical trial NCT07018401?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07018401 being conducted?
This trial has 11 study locations across California, Florida, Maryland, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Hemorrhagic Telangiectasia (HHT)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.